106 related articles for article (PubMed ID: 8478175)
1. Magnetic resonance imaging after arterial portography with manganese dipyridoxal diphosphate.
Nelson RC; Chezmar JL; Thompson GH; Webber JB; Garrison MH; Spencer HB; Dillehay DL
Invest Radiol; 1993 Apr; 28(4):335-40. PubMed ID: 8478175
[TBL] [Abstract][Full Text] [Related]
2. Mangafodipir trisodium (MnDPDP)-enhanced magnetic resonance imaging of the liver and pancreas.
Wang C
Acta Radiol Suppl; 1998; 415():1-31. PubMed ID: 9571956
[TBL] [Abstract][Full Text] [Related]
3. MnDPDP as a negative hepatic contrast agent: evaluation of STIR imaging compared with T1-weighted SE and GE techniques.
Halavaara JT; Lamminen AE
J Comput Assist Tomogr; 1997; 21(1):94-9. PubMed ID: 9022776
[TBL] [Abstract][Full Text] [Related]
4. Comparison of manganese biodistribution and MR contrast enhancement in rats after intravenous injection of MnDPDP and MnCl2.
Ni Y; Petré C; Bosmans H; Miao Y; Grant D; Baert AL; Marchal G
Acta Radiol; 1997 Jul; 38(4 Pt 2):700-7. PubMed ID: 9245965
[TBL] [Abstract][Full Text] [Related]
5. Pancreatic enhancement after low-dose infusion of Mn-DPDP.
Gehl HB; Vorwerk D; Klose KC; Günther RW
Radiology; 1991 Aug; 180(2):337-9. PubMed ID: 1906189
[TBL] [Abstract][Full Text] [Related]
6. MnDPDP enhancement in rabbit liver after intravenous bolus injection and slow infusion.
Thorstensen O; Isberg B; Jorulf H; Westman L; Svahn U; Venizelos N
Acta Radiol; 1997 Jul; 38(4 Pt 2):717-23. PubMed ID: 9245967
[TBL] [Abstract][Full Text] [Related]
7. MR imaging properties and pharmacokinetics of MnDPDP in healthy volunteers.
Wang C; Gordon PB; Hustvedt SO; Grant D; Sterud AT; Martinsen I; Ahlström H; Hemmingsson A
Acta Radiol; 1997 Jul; 38(4 Pt 2):665-76. PubMed ID: 9245962
[TBL] [Abstract][Full Text] [Related]
8. Hepatobiliary MR imaging: first human experience with MnDPDP.
Lim KO; Stark DD; Leese PT; Pfefferbaum A; Rocklage SM; Quay SC
Radiology; 1991 Jan; 178(1):79-82. PubMed ID: 1898539
[TBL] [Abstract][Full Text] [Related]
9. Clinical implications of studies with MnDPDP in animal models of hepatic abnormalities.
Ni Y; Marchal G
Acta Radiol; 1997 Jul; 38(4 Pt 2):724-31. PubMed ID: 9245968
[TBL] [Abstract][Full Text] [Related]
10. Overview of MnDPDP as a pancreas-specific contrast agent for MR imaging.
Ahlström H; Gehl HB
Acta Radiol; 1997 Jul; 38(4 Pt 2):660-4. PubMed ID: 9245961
[TBL] [Abstract][Full Text] [Related]
11. The uptake of manganese dipyridoxal-diphosphate by chemically induced hepatocellular carcinoma in rats. A correlation between contrast-media-enhanced magnetic resonance imaging, tumor differentiation, and vascularization.
Ni Y; Marchal G; Zhang X; Van Hecke P; Michiels J; Yu J; Rummeny E; Lodemann KP; Baert AL
Invest Radiol; 1993 Jun; 28(6):520-8. PubMed ID: 8320070
[TBL] [Abstract][Full Text] [Related]
12. Preclinical evaluation of MnDPDP: new paramagnetic hepatobiliary contrast agent for MR imaging.
Elizondo G; Fretz CJ; Stark DD; Rocklage SM; Quay SC; Worah D; Tsang YM; Chen MC; Ferrucci JT
Radiology; 1991 Jan; 178(1):73-8. PubMed ID: 1898538
[TBL] [Abstract][Full Text] [Related]
13. Effects of manganese dipyridoxyl diphosphate, dipyridoxyl diphosphate--, and manganese chloride on cardiac function. An experimental study in the Langendorff perfused rat heart.
Brurok H; Schjøtt J; Berg K; Karlsson JO; Jynge P
Invest Radiol; 1995 Mar; 30(3):159-67. PubMed ID: 7797414
[TBL] [Abstract][Full Text] [Related]
14. Technical report: lymph node enhancement at MRI with MnDPDP in primary hepatic carcinoma.
Burkill GJ; Mannion EM; Healy JC
Clin Radiol; 2001 Jan; 56(1):67-71. PubMed ID: 11162701
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of mangafodipir trisodium (MnDPDP) injection for hepatic MRI in adults: results of the U.S. Multicenter phase III clinical trials. Efficacy of early imaging.
Federle M; Chezmar J; Rubin DL; Weinreb J; Freeny P; Schmiedl UP; Brown JJ; Borrello JA; Lee JK; Semelka RC; Mattrey R; Dachman AH; Saini S; Harms SE; Mitchell DG; Anderson MW; Halford HH; Bennett WF; Young SW; Rifkin M; Gay SB; Ballerini R; Sherwin PF; Robison RO
J Magn Reson Imaging; 2000 Nov; 12(5):689-701. PubMed ID: 11050638
[TBL] [Abstract][Full Text] [Related]
16. Manganese dipyridoxal diphosphate-enhanced magnetic resonance imaging in the evaluation of hepatocyte function.
Sidhu MK; Muller HH; Aggeler J; Jones AL; Young SW
Invest Radiol; 1993 Oct; 28(10):903-10. PubMed ID: 8262744
[TBL] [Abstract][Full Text] [Related]
17. Evidence for the dissociation of the hepatobiliary MRI contrast agent Mn-DPDP.
Gallez B; Bacic G; Swartz HM
Magn Reson Med; 1996 Jan; 35(1):14-9. PubMed ID: 8771018
[TBL] [Abstract][Full Text] [Related]
18. Mangafodipir trisodium-enhanced magnetic resonance imaging for evaluation of pancreatic mass and mass-like lesions.
Eser G; Karabacakoglu A; Karakose S; Eser C; Kayacetin E
World J Gastroenterol; 2006 Mar; 12(10):1603-6. PubMed ID: 16570354
[TBL] [Abstract][Full Text] [Related]
19. Axon tracing in the adult rat optic nerve and tract after intravitreal injection of MnDPDP using a semiautomatic segmentation technique.
Olsen Ø; Thuen M; Berry M; Kovalev V; Petrou M; Goa PE; Sandvig A; Haraldseth O; Brekken C
J Magn Reson Imaging; 2008 Jan; 27(1):34-42. PubMed ID: 18157895
[TBL] [Abstract][Full Text] [Related]
20. MRI measurement of hepatocyte toxicity using the new MRI contrast agent manganese dipyridoxal diphosphate, a manganese/pyridoxal 5-phosphate chelate.
Young SW; Simpson BB; Ratner AV; Matkin C; Carter EA
Magn Reson Med; 1989 Apr; 10(1):1-13. PubMed ID: 2502699
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
